Key statistics
As of last trade Ionis Pharmaceuticals Inc (ISI:DUS) traded at 67.68, -7.57% below its 52-week high of 73.22, set on Jan 07, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 67.54 |
|---|---|
| High | 67.68 |
| Low | 67.54 |
| Bid | 67.72 |
| Offer | 68.74 |
| Previous close | 68.42 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 161.97m |
| Free float | 160.88m |
| P/E (TTM) | -- |
| Market cap | 13.06bn USD |
| EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 11:31 GMT.
More ▼
Press releases
- Ionis to hold fourth quarter and full year 2025 financial results webcast
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
- Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
- Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
- Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
- Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
More ▼
